Skip to main
KZR

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences Inc. has garnered a positive outlook due to the lifting of the partial clinical hold on its therapeutic candidate, Zetomipzomib (KZR-616), for the treatment of autoimmune hepatitis (AIH), which enhances investor confidence in its risk-benefit profile. The potential full removal of the clinical hold in lupus nephritis (LN) could significantly bolster investor confidence and facilitate eventual clinical uptake if approved, presenting an opportunity for market expansion. These developments suggest a favorable trajectory for the company's pipeline and potential commercial viability of its assets in addressing significant unmet medical needs in both autoimmunity and cancer.

Bears say

Kezar Life Sciences Inc. is currently facing significant challenges due to its clinical-stage status, which inherently carries high risk and uncertainty regarding the success of its product candidates, Zetomipzomib (KZR-616) and KZR-261. The company has reported limited progress in advancing its pipeline, coupled with escalating research and development expenditures that could strain financial resources, especially if trials do not yield favorable outcomes. Additionally, the lack of diversified revenue streams and reliance on breakthrough results further contribute to a cautious sentiment regarding the company's future financial performance.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.